Tuberculosis Diagnosis and Detection of Drug Resistance: A Comprehensive Updated Review

IF 0.7 Q4 MICROBIOLOGY
M. Tawfick, M. E. S. M. Badawy, M. H. Taleb, N. E. El Menofy
{"title":"Tuberculosis Diagnosis and Detection of Drug Resistance: A Comprehensive Updated Review","authors":"M. Tawfick, M. E. S. M. Badawy, M. H. Taleb, N. E. El Menofy","doi":"10.22207/jpam.17.4.56","DOIUrl":null,"url":null,"abstract":"Tuberculosis (TB) is a significant public health challenge, especially in developing nations. Developing a TB eradication strategy is hampered by the global health concern of drug-resistant (DR) TB. Effective patient treatment, preventing TB transfer and avoiding the upsurge of DR strains depend primarily on the timely and accurate identification of DR TB. Due to inadequate sensitivity, the necessity of trained laboratory personnel, the sluggish growth pattern of Mycobacterium bacilli in culture, and the small number of bacilli that are usually found in extrapulmonary TB samples, TB diagnosis is still tricky in clinical practice. Although mycobacterial culture is the gold standard to identify TB and determine drug resistance, it takes 2 to 8 weeks to develop. Despite their high cost, nucleic acid amplification tests (NAATs) and whole-genome sequencing (WGS) are the commonly employed molecular-based methods for diagnosing and identifying TB. The WHO suggested the GeneXpert MTB/RIF to identify TB and detect resistance to rifampicin. In comparison, numerous molecular techniques were developed, including allele-specific PCR (MAS-PCR), solid-phase hybridization, real-time PCR (RT-PCR) and droplet digital PCR-based technique (DDPCR). This manuscript is intended to overview the current approaches for the phenotypic and genotypic diagnosis of TB disease and identifying resistance to antitubercular drugs depending on recently published articles, WHO and CDC reports, and commercially available diagnostic tools.","PeriodicalId":16968,"journal":{"name":"Journal of Pure and Applied Microbiology","volume":"121 44","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pure and Applied Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22207/jpam.17.4.56","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis (TB) is a significant public health challenge, especially in developing nations. Developing a TB eradication strategy is hampered by the global health concern of drug-resistant (DR) TB. Effective patient treatment, preventing TB transfer and avoiding the upsurge of DR strains depend primarily on the timely and accurate identification of DR TB. Due to inadequate sensitivity, the necessity of trained laboratory personnel, the sluggish growth pattern of Mycobacterium bacilli in culture, and the small number of bacilli that are usually found in extrapulmonary TB samples, TB diagnosis is still tricky in clinical practice. Although mycobacterial culture is the gold standard to identify TB and determine drug resistance, it takes 2 to 8 weeks to develop. Despite their high cost, nucleic acid amplification tests (NAATs) and whole-genome sequencing (WGS) are the commonly employed molecular-based methods for diagnosing and identifying TB. The WHO suggested the GeneXpert MTB/RIF to identify TB and detect resistance to rifampicin. In comparison, numerous molecular techniques were developed, including allele-specific PCR (MAS-PCR), solid-phase hybridization, real-time PCR (RT-PCR) and droplet digital PCR-based technique (DDPCR). This manuscript is intended to overview the current approaches for the phenotypic and genotypic diagnosis of TB disease and identifying resistance to antitubercular drugs depending on recently published articles, WHO and CDC reports, and commercially available diagnostic tools.
结核病诊断与耐药性检测:最新全面综述
结核病是一项重大的公共卫生挑战,特别是在发展中国家。制定根除结核病战略受到耐药结核病全球卫生问题的阻碍。有效的患者治疗、预防结核病转移和避免耐多药菌株激增主要取决于及时和准确地识别耐多药结核病。由于敏感性不足,需要训练有素的实验室人员,培养中杆菌生长模式缓慢,以及通常在肺外结核样本中发现的杆菌数量较少,结核病诊断在临床实践中仍然很棘手。虽然分枝杆菌培养是鉴定结核病和确定耐药性的金标准,但需要2至8周的时间才能形成。尽管成本高昂,核酸扩增试验(NAATs)和全基因组测序(WGS)是诊断和鉴定结核病常用的基于分子的方法。世卫组织建议GeneXpert MTB/RIF识别结核病并检测对利福平的耐药性。相比之下,许多分子技术被开发出来,包括等位基因特异性PCR (MAS-PCR)、固相杂交、实时PCR (RT-PCR)和基于液滴数字PCR的技术(DDPCR)。本文旨在根据最近发表的文章、世卫组织和疾病预防控制中心的报告以及市售诊断工具,概述目前用于结核病的表型和基因型诊断和确定抗结核药物耐药性的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pure and Applied Microbiology
Journal of Pure and Applied Microbiology BIOTECHNOLOGY & APPLIED MICROBIOLOGY-MICROBIOLOGY
CiteScore
2.00
自引率
0.00%
发文量
266
审稿时长
11 months
期刊介绍: Journal of Pure and Applied Microbiology (JPAM) is a peer-reviewed, open access international journal of microbiology aims to advance and disseminate research among scientists, academics, clinicians and microbiologists around the world. JPAM publishes high-quality research in all aspects of microbiology in both online and print form on quarterly basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信